(Press-News.org) Levels of antibodies in the blood of vaccinated people that are able to recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre, published today (Thursday) as a Research letter in The Lancet.
The results also show that levels of these antibodies are lower with increasing age and that levels decline over time, providing additional evidence in support of plans to deliver a vaccination boost to vulnerable people in the Autumn.
And, the researchers support current plans to reduce the dose gap between vaccines since they found that after just one dose of the Pfizer-BioNTech vaccine, people are less likely to develop antibody levels against the B.1.617.2 (Delta) variant as high as those seen against the previously dominant B.1.1.7 (Alpha) variant, first found in Kent.
Although laboratory results such as these are needed to provide a guide as to how the virus might be evolving to escape the first generation of vaccines, levels of antibodies alone do not predict vaccine effectiveness and prospective population studies are also needed. Lower neutralising antibody levels may still be associated with protection against COVID-19.
This is the largest study published to date investigating vaccine-induced antibody neutralising capacity against the newest variants of concern in healthy adults. Researchers have submitted their findings to the Genotype-to-Phenotype National Virology Consortium (G2P-UK), the New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) and the Joint Committee on Vaccination and Immunisation (JCVI), as evidence of the level of protection people might receive against the new variants after one dose and both doses of the Pfizer COVID-19 vaccine.
As part of the SARS-CoV-2 Legacy study, led by the Crick and partners at UCL and University College London Hospitals NHS Foundation Trust (UCLH), healthcare workers and staff from the institutions have been donating regular blood and swab samples so that researchers can track changing risk of infection and response to vaccination.
Thanks to samples of the latest variants of concern being provided by NHS labs to the G2P-UK consortium, researchers have been able to quickly assess the potential risks they might pose.
Within just a few days of having enough of each variant to study, they were able to analyse antibodies in the blood of 250 healthy people who received either one or two doses of the Pfizer-BioNTech Covid-19 vaccine, up to three months after their first dose. Using a new highly accurate high throughput viral neutralisation assay developed at the Crick, they tested the ability of antibodies to block entry of the virus into cells, so called 'neutralising antibodies', against five different variants of SARS-CoV-2:
- The original strain first discovered in Wuhan, China
- The dominant strain in Europe during the first wave in April 2020 (D614G)
- B.1.1.7, the variant first discovered in Kent, UK (Alpha)
- B.1.351, the variant first discovered in South Africa (Beta)
- B.1.617.2, the newest variant of concern, first discovered in India (Delta)
They then compared concentrations of these neutralising antibodies between all variants. Data from previous clinical studies suggests that higher antibody titres (the greatest dilution level that still blocks 50% of virus infection in the lab) is a good predictor of vaccine efficacy and greater protection against COVID-19.
They found that in people who had been fully vaccinated with two doses of the Pfizer-BioNTech vaccine, levels of neutralising antibodies were more than five times lower against the B.1.617.2 variant when compared to the original strain, upon which current vaccines are based.
Importantly, this antibody response was even lower in people who had only received one dose. After a single dose of Pfizer-BioNTech, 79% of people had a quantifiable neutralising antibody response against the original strain, but this fell to 50% for B.1.1.7, 32% for B.1.617.2 and 25% for B.1.351.
While antibody levels decreased with age against all variants, no correlation was observed for sex or BMI.
The study participants analysed here had all been vaccinated with the Pfizer-BioNTech vaccine. More work is underway to test neutralising antibodies against these same variants in people who have been vaccinated with the Oxford/AstraZeneca vaccine.
Emma Wall, UCLH Infectious Diseases consultant and Senior Clinical Research Fellow for the Legacy study, said: "This virus will likely be around for some time to come, so we need to remain agile and vigilant. Our study is designed to be responsive to shifts in the pandemic so that we can quickly provide evidence on changing risk and protection.
"The most important thing is to ensure that vaccine protection remains high enough to keep as many people out of hospital as possible. And our results suggest that the best way to do this is to quickly deliver second doses and provide boosters to those whose immunity may not be high enough against these new variants."
David LV Bauer, group leader of the Crick's RNA Virus Replication Laboratory and member of the G2P-UK National Virology Consortium, said: "New variants occur naturally and those that have an advantage will spread. We now have the ability to quickly adapt our vaccination strategies to maximise protection where we know people are most vulnerable.
"Keeping track of these evolutionary changes is essential for us to retain control over the pandemic and return to normality. This work is a powerful example of effective collaborations between NHS and academic colleagues, that can help us to navigate changes in this new phase of the pandemic."
INFORMATION:
For further information, contact: press@crick.ac.uk or +44 (0)20 3796 5252
Notes to Editors
Wall, E. C., Wu M. et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. The Lancet. 2021
Post embargo link: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01290-3/fulltext
Research letters published in the Correspondence section include research findings and are externally peer-reviewed. Unlike Articles containing original data, research letters are shorter and the research they contain is usually preliminary, exploratory, or reporting on early findings.
Francis Crick Institute and UCLH Biomedical Research Centre press release
Under strict embargo: 23:30hrs BST Thursday June 3, 2021
Peer reviewed
Observational study
People
An immunotherapy drug given after surgery improved disease-free survival rates in patients with kidney cancer at high risk of relapse.
Interim results of a phase 3 trial of adjuvant therapy revealed a 32% decrease in the risk of recurrence or death with pembrolizumab compared with a placebo
This is the first positive study of immunotherapy in patients with kidney cancer at high risk of relapse.
BOSTON -- Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim ...
Sickle cell disease (SCD) is the most common deadly genetic disorder, affecting more than 300,000 newborns worldwide each year. It leads to chronic pain, organ failure, and early death in patients. A team led by researchers at the Broad Institute of MIT and Harvard and St. Jude Children's Research Hospital has now demonstrated a base editing approach that efficiently corrects the mutation underlying SCD in patient blood stem cells and in mice. This gene editing treatment rescued the disease symptoms in animal models, enabling the long-lasting production of healthy blood cells.
The root of SCD is two mutated copies of the hemoglobin gene, HBB, which cause red ...
After a 2020 Vanderbilt University Medical Center study showed women have a difficult time accessing treatment for opioid use disorder (OUD), investigators analyzed comments received from the study's participants to further shed light on barriers to care, which included everything from long on-hold times to difficult interactions with clinic receptionists during phone calls seeking appointments.
A "secret shopper" study published in JAMA Network Open in 2020 used trained actors trying to get into treatment for opioid use disorder in 10 U.S. states. More than 10,000 unique "patients" were randomly assigned to be pregnant or non-pregnant and have private or Medicaid-based insurance to assess differences ...
MEMPHIS, Tenn. - Cardiovascular imaging demonstrated no evidence of myocardial injury or myocarditis in athletes after COVID-19 infection, according to a research letter published in Circulation by Le Bonheur Children's Hospital and the University of Tennessee Health Science Center cardiologists. The screening and evaluation was conducted by the Le Bonheur Children's Heart Institute Sports Cardiology team, Benjamin S. Hendrickson, MD, Ranjit R. Philip, MD, and Ryan E. Stephens, NP-C, MBA, and Le Bonheur Director of Cardiac MRI Jason N. Johnson, MD, MHS. Researchers say this study confirms existing recommendations ...
The North American mockingbird is famous for its ability to imitate the song of other birds. But it doesn't just mimic its kindred species, it actually composes its own songs based on other birds' melodies. An interdisciplinary research team has now worked out how exactly the mockingbird constructs its imitations. The scientists determined that the birds follow similar musical rules as those found in human music, from Beethoven to Kendrick Lamar.
The song of the mockingbird is so complex that to investigate it required a joint effort of experts from very different fields. Neuroscientist Tina Roeske of the Max Planck Institute for Empirical Aesthetics, field biologist Dave Gammon of Elon University, ...
COVID-19 continues to claim lives across the world and is infecting millions more. Although several vaccines have recently become available, making significant strides towards preventing COVID-19, what about the treatment of those who already have the infection? Vaccines aren't 100% effective, highlighting the need--now more than ever--for effective antiviral therapeutics. Moreover, some people can't receive vaccines due to health issues, and new variants of SARS-CoV-2, the virus that causes COVID-19, that can penetrate vaccine-conferred immunity, are being reported, indicating that we need to think beyond prevention.
Given this need, a team of researchers based in Japan, the US, and the UK launched a project to develop effective therapeutics. ...
Stanford University computer science graduate student Mackenzie Leake has been quilting since age 10, but she never imagined the craft would be the focus of her doctoral dissertation. Included in that work is new prototype software that can facilitate pattern-making for a form of quilting called foundation paper piecing, which involves using a backing made of foundation paper to lay out and sew a quilted design.
Developing a foundation paper piece quilt pattern - which looks similar to a paint-by-numbers outline - is often non-intuitive. There are few formal guidelines for patterning and those that ...
Humans regularly exert a powerful influence on the survival and persistence of species, yet social-science information is used only sporadically in conservation decisions.
Researchers at Colorado State University and The Ohio State University have created an index depicting the mix of social values among people across all 50 states, providing data that can be useful for wildlife conservation policy and management.
As a specific illustration, the research team found a supportive social context for gray wolf reintroduction in Colorado. Last fall, citizens ...
NEW YORK CITY, June 2, 2021 -- New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo®) after bladder cancer surgery reduced their overall risk for high-grade bladder cancer recurrence. This research was published in the New England Journal of Medicine.
In this phase III randomized study, Dr. Bajorin and a team of investigators evaluated 709 patients who were at high risk for recurrence of urothelial cancer after removal of their bladder, ureter, or kidney for high-grade cancer. To evaluate for benefit, patients were randomized to receive either nivolumab or a placebo every two weeks for one year. Patients and ...
A complex zone of folding and faulting that links two faults underneath downtown Salt Lake City could deform the ground during a large earthquake, according to a new study.
The findings, published in the open-access journal The Seismic Record, suggest that earthquakes magnitude 5.0 and larger could cause ground displacement and liquefaction in Salt Lake City that increase the risk of earthquake-related building damage.
As part of the Wasatch Fault Zone, the region has a complex seismic history, with at least 24 large earthquakes occurring in the urbanized parts of the zone over the past 7000 years. Along with previous excavation, borehole and other geophysical studies, the new research also supports the possibility of through-going ruptures ...
